Healthcare

Addiction Biotech Cannabis Genetics Healthcare Medical Devices Pharmaceutical Science Veterinary
News Release Digital Asset Direct

Over 60 million Medicare Beneficiaries Will Need To Decide Whether to Stick With Their Plan Or Change This Fall – Here Are Some Tips for Making The Best Dental Plan Choice

DentalPlans.com

By Rachael Green, Benzinga Open enrollment for Medicare is set to begin on October 15 this year, meaning the 60 million Americans already enrolled along with newly eligible beneficiaries will be reading up on the upcoming changes to their plans and comparing the coverage options this fall. Since dental benefits can vary from one Medicare Advantage plan to the next and aren’t included at all in Original Medicare, it can be tough to figure out what the best fit is. Because of this, many look to dental insurance alternatives, like dental savings plans. Make sure you’re fully prepared to make the best dental plan choice for you and your family by following these steps. 1. Make A List Of Your Anticipated Dental Care Needs Finding the best plan for you involves more than just choosing the cheapest premium. Ultimately, the way to save the most money is to choose the plan that provides the biggest savings of all – or as much as possible – of the care you need or may need. To find that plan, it helps to have a list of everything you want included. If you wear dentures, for example, you might need more than the standard cleanings and checkups, like denture resizing or replacement. If your dentist recommended multiple root canals or other complicated care and you’re waiting for the new year to finish the work when your coverage resets, now is definitely the time to look for a plan that offers a higher annual maximum – or no annual maximum – and no preexisting condition exclusions on the work you need. 2. Read The Plan Annual Notice Of Change You Get This Month Carefully If you are already enrolled in a plan that includes dental benefits, your current provider should send you a Plan Annual Notice of Change (ANOC) sometime this month. This will detail any changes to the costs or coverages in your plan. Read through this carefully so you can decide whether the new policy will still meet your needs based on that list of anticipated needs you made earlier. That way, if it doesn’t, you can start shopping around now to switch, drop the plan or add additional savings plans when open enrollment starts. 3. Compare Your Medicare Advantage Options — Even If You’re Happy With Your Current Plan Insurance companies can join or leave Medicare every year. That means there is always the risk that your current provider will leave, forcing you to choose a new plan or go back to Original Medicare. But it also means that new plans that are now available might be even better suited to your needs than the one you’re currently on. So it’s worth it to shop around and compare your options ahead of every open enrollment period, regardless of how happy you are with your current plan. There are also options outside of Medicare Advantage and Original Medicare that may better meet your needs. This is especially true when it comes to dental benefits which tend to be more limited and restrictive. If you know you’re going to need more than the routine dental cleaning and checkups next year, you could be leaving serious benefits on the table if you don’t shop around to see if there’s a new option with better dental coverage than your current plan. 4. Consider Adding A Dental Savings Plan To The Mix To Cut Costs While MA plans typically offer dental, vision and prescription drug benefits, they can often come with low annual limits or other coverage restrictions that make them less cost-effective in the long run. One way to ensure you can keep costs down is to sign up for a dental savings plan. These plans aren’t insurance. They are a trusted alternative to dental insurance. Plan members pay a low annual fee for access to savings on virtually all dental procedures, from routine preventative care to restorative dental procedures and even cosmetic dental care like dental implants, which insurance usually does not cover. Plan members report an average savings of 50%* on their dental care at over 140,000 participating dentists and specialists nationwide. These plans have no annual limit, no restrictions based on current health conditions or existing dental concerns, and are activated within 1-3 business days. They are a great compliment to any Medicare plan. Some plans also include similar discounts for other care that’s not covered by Original Medicare like vision, hearing or prescription drugs. Finding the best plan to save you money on your dental care as a Medicare beneficiary doesn’t have to be complicated. Compare your Medicare options, and then head to DentalPlans.com to compare dental plan options. You can get a personalized dental plan recommendation online in minutes – or give their expert team a call. Visit DentalPlans.com today and be ready for open enrollment. * Discount Health Program consumer & provider surveys indicate average savings of 50%. Savings may vary by provider, location, and plan. DentalPlans.com, founded in 1999, is a leading online marketplace for dental savings plans in the U.S., helping more than a million people to affordably access quality healthcare services. Our mission is to empower consumers with the tools, information, and services that they need to live happier, healthier lives. This post contains sponsored content. This content is for informational purposes only and not intended to be investing advice. Contact Details Matthew Wong matthew.wong@wpromote.com Company Website https://www.dentalplans.com/

October 03, 2023 09:00 AM Eastern Daylight Time

Only-Of-Its-Kind Filterbaby Launches on Thirteen Lune

Filterbaby

Filterbaby, the first and only clinically tested and dermatologist recommended skincare water filter for the face is expanding its retail footprint. The brand has launched on Thirteen Lune, the popular E-Commerce site for minority founded beauty brands. Since its 2022 inception, Filterbaby has seen tremendous growth; selling nearly 100,000 units and garnering over half a million followers on social media and one billion views on Instagram, Tiktok and Youtube. "We at Filterbaby are absolutely elated to be welcomed into the Thirteen Lune community. This remarkable space, dedicated to empowering minority founders, resonates deeply with our values and aspirations. We are putting a flag on the ground stating that water quality significantly impacts skin; our mission is to transform people’s life through better water. We are so glad that Thirteen Lune is providing the ideal platform to amplify our mission. We're honored to join this collective force for positive change in the beauty industry." said Xin Shui, CEO/Founder of Filterbaby. While millions of skincare products flood the market, there is a striking absence of emphasis on the quality of water, a fundamental factor essential for achieving good facial skin health. Consumers spend thousands of dollars on skincare each year to optimize their skin health, yet the most fundamental element, water used to clean skin, is often subpar. Filterbaby’s founder is a third-generation female healthcare provider who had experience of treating over 10,000 patients. She discerned a profound correlation that exists between water quality and skin health. “There is a real necessity for this product as tap water quality is subpar in most states with excess chlorine or chloramine, microplastics, hard metals, unregulated chemicals, and infrastructure issues. Over the past few months, we received hundreds of before and after photos from customers with skin specific issues from eczema, rosacea, acne prone and dry skin who saw drastic improvements using Filterbaby,” explains Xin. By filtering impurities and micro-contaminants in tap water as small as 0.2 microns, Filterbaby ensures users receive higher quality water to improve their skin's health. It is clinically tested to improve skin hydration in just 2 weeks. Through consumer studies, it is also found to reduce irritation, protect epidermis, ultimately leading to radiant and healthier skin. In addition to Thirteen Lune, Filterbaby is sold on www.filterbaby.com as well as Amazon, Urban Outfitters, Bloomingdales.com and Dormify.com. Their starter kit retails for $89. About Thirteen Lune: Thirteen Lune is an e-commerce destination designed to inspire the discovery of beauty brands created by Black and Brown founders that resonate with people of all colors. It reframes how Black, Brown and minority founded beauty brands are perceived not only from an industry perspective, but also for the consumer giving each brand a platform to educate and engage a wider audience. About Filterbaby: Research shows that most US households’ tap water contains chlorine, micro-plastics, heavy metals, and hundreds of unregulated chemicals. Filterbaby was created to reduce all of these skin irritating and harming pollutants. The brand has undergone certified third-party skin hydration lab measurement testing which showed that the filter helps increase hydration within two weeks of use. Clinically tested & dermatologist-recommended, made for skincare. Healthier skin starts with your water. Available on www.filterbaby.com, Amazon, Urban Outfitters, Dormify.com Bloomingdales.com and Thirteen Lune. Contact Details Colleen Mathis absolute R relations colleen@absoluteRrelations.com

October 03, 2023 08:00 AM Eastern Daylight Time

News Release

NuggMD Launches Its Leading Marijuana Telemedicine Service in Delaware

NuggMD

NuggMD, the nation's leading medical marijuana telemedicine platform, is launching its service in Delaware for just $99 for a limited time. Since its founding in 2015, NuggMD has connected over 1,000,000 patients to their medical marijuana physicians. It's legal to possess and use cannabis in the state, but adult-use sales aren't expected to begin until November 2024 at the soonest, and more likely later in 2025. Medical patients in the state opposed the option to allow the existing, tightly-regulated medical dispensaries to begin adult-use sales earlier due to fears that there wouldn't be enough cannabis to serve both medical and recreational needs, which would cause a spike in prices. "It's understandable that patients would be worried about a spike in prices with an uncontrolled launch of recreational sales," says Alex Milligan, CMO and co-founder of NuggMD. "It has happened in other states, leaving patients in a bad situation. But the current situation brings about other safety concerns. State residents can possess cannabis and use it legally, but can't buy safe, tested weed unless they're patients." "I don't suggest you turn to the black market while waiting for dispensaries to open," says Kam Babazade, COO and co-founder of NuggMD. "Recent tests on black market products on the East Coast have shown contaminants, synthetic cannabinoids, and major discrepancies in potency. This is something you especially want to avoid if you have significant medical issues." "We have diverted over a million patients from the black market now," says Collin Mann, NuggMD co-founder and CEO. "Delaware was wise to allow telemedicine so even more patients can be turned toward the legal, tested, and safe products in the state's existing dispensaries." NuggMD's platform is available from 8 am to 10 pm seven days a week. No appointment is needed, and patients who don't qualify for their state's medical cannabis program won't be charged for their evaluation. About NuggMD NuggMD is the nation's leading medical marijuana technology platform, serving patients in California, Connecticut, Delaware, Georgia, Illinois, Iowa, Louisiana, Maine, Maryland, Massachusetts, Michigan, Minnesota, Missouri, Delaware, Nevada, New Jersey, New York, Ohio, Oklahoma, Pennsylvania, Texas, Vermont, Virginia, Washington, and West Virginia. They've connected over 1,000,000 patients face-to-face with their new medical marijuana doctors via their state-of-the-art telemedicine platform. They believe every human being has the right to explore the benefits of medical cannabis and are fully committed to helping each patient explore every option in their journey to wellness. For further information, visit NuggMD.com/Delaware. Contact Details Andrew Graham +1 646-385-0189 andrew.g@getnugg.com Company Website http://www.nuggmd.com

October 02, 2023 05:28 PM Eastern Daylight Time

News Release

Redsense Medical announces company has begun trading on the OTCQX under ticker 'RDSMF'

Redsense Medical

Redsense Medical CEO Pontus Nobreus joined Steve Darling from Proactive to share significant updates regarding the company's innovative Redsense System. This system plays a crucial role in monitoring and alerting healthcare providers in cases of blood leakage during hemodialysis treatments, addressing one of the most serious safety concerns in this medical field. The Redsense System comprises a patented fiber optic sensor designed for use with either a venous needle or central venous catheter, linked to an alarm unit. The system has been developed with a strong focus on meeting the stringent safety requirements of healthcare providers in the dialysis sector. Alarmingly, globally, 21 individuals lose their lives each week due to blood leakage during hemodialysis, making this technology a critical advancement in patient care. One major development for Redsense Medical is its recent listing on the OTCQX market under the ticker symbol 'RDSMF.' The United States is a pivotal market for the company, with 99% of its revenue in 2022 generated from the US. The company is actively planning to expand its presence in the US market, providing easier access for US investors to participate in their growth journey. Looking ahead to the remainder of 2023 and 2024, Redsense Medical has ambitious goals, including continued growth in the US market and raising awareness about the importance of monitoring devices in home dialysis. Additionally, the company is set to launch a new product called "The Clamp," which will further enhance patient safety during hemodialysis treatments. Overall, Redsense Medical's dedication to improving patient safety and healthcare outcomes in the field of hemodialysis positions it as a key player in the medical technology industry, and its expansion plans in the US market are poised to make a significant impact. Contact Details Proactive Investors +1 604-688-8158 na-editorial@proactiveinvestors.com

September 29, 2023 01:39 PM Eastern Daylight Time

Video

News Release

Spectral AI announces "single largest contract to date"

Spectral AI Inc

Spectral AI Ltd (NASDAQ:MDAI) founder and CEO Wensheng Fan speaks to Thomas Warner from Proactive after the medical-focused artificial intelligence company announced it has been awarded a new contract valued at up to $149 million by the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services. The CEO describes the contract as Spectral AI's "single largest to date" and highlights that it represents an important step forward in its commercial efforts. The deal includes a base phase of $55mln for FDA clearance of "Deep View" in burn indication. The technology aims to assist ER physicians in determining whether burn patients should be transferred to specialized burn centers. With 1.1 million burns occurring in the US annually, the potential for Deep View's application in emergency rooms and trauma centers is vast. Additionally, the technology will play a role in the treatment flow of both burn and diabetic foot ulcers, further expanding its clinical utility. Fan explains that following Spectral's recent move from London's AIM to the NASDAQ, the contract signifies a pivotal moment in the company's history, cementing its commercial future and revealing more about its potential impact on the healthcare sector. Contact Details Proactive Investors +44 20 7989 0813 uk@proactiveinvestors.com

September 29, 2023 01:17 PM Eastern Daylight Time

Video

Accelmed Files Transaction Statement on Schedule 13E-3 with Securities and Exchange Commission

Accelmed

Today Minerva Surgical, Inc. (the “Company”) (Nasdaq: UTRS), entered into a share purchase agreement (the “Purchase Agreement”) for the sale of an aggregate of 97,751,711 shares (the “Shares”) of its common stock (“Common Stock”) in a private placement (the “Private Placement”) by the Company to Accelmed Partners II L.P. (“Accelmed LP”), at an offering price of $0.2046 per share, for aggregate consideration of $20,000,000.07. In connection with a contemplated refinancing by the Company of its Loan and Security Agreement, dated as of October 8, 2021, by and among the Company, the Canadian Imperial Bank of Commerce, and each other person party thereto, as a borrower from time to time, as amended (the “Loan and Security Agreement”, and such refinancing, the “Refinancing”), it is expected that potential lenders shall require as a condition to the Refinancing that the Company complete a equity financing of at least $20,000,000 prior to the Refinancing (the “Lender’s Refinancing Condition”). As of the date hereof, Accelmed LP owns 68.8% of the issued and outstanding shares of Common Stock of the Company, based upon 177,573,152 shares of Common Stock issued and outstanding on September 14, 2023, as reported by the Company in the Purchase Agreement. Upon the closing of the Private Placement, Accelmed LP will own 79.9% of the issued and outstanding shares of Common Stock of the Company, based upon 177,573,152 shares of Common Stock issued and outstanding on September 14, 2023, as reported by the Company in the Purchase Agreement. As the Private Placement may be viewed as a step in a series of transactions, which constitute a “going-private” transaction under Rule 13e-3 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), Accelmed LP, Accelmed Partners II GP L.P., Accelmed Partners II, LLC and Uri Geiger (collectively, the “Filing Persons”) have filed a transaction statement on Schedule 13E-3 (“Transaction Statement”) with the United States Securities and Exchange Commission (the “SEC”). The Filing Persons have previously disclosed that they are considering effecting a transaction pursuant to which (i) the Common Stock may be delisted from trading on the Nasdaq Capital Market (“Nasdaq”); and (ii) the registration of the Common Stock under the Exchange Act would be terminated (a “Take Private Transaction”). In connection with such potential Take Private Transaction, Accelmed LP has previously disclosed that it is evaluating acquiring shares of Common Stock from existing stockholders in one or more privately negotiated transactions and may discuss such privately negotiated transactions with certain existing stockholders of the Company. The Private Placement is not being conducted in conjunction with any Take Private Transaction, but rather to satisfy the Lender’s Refinancing Condition. The closing of the Private Placement is subject to the condition that the terms of the Refinancing are acceptable to Accelmed LP, in its sole and absolute discretion, and other customary closing conditions. The closing of the Private Placement may not take place prior to October 28, 2023. No assurances can be made that the Private Placement will close, that the Refinancing will occur, or that any Take Private Transaction will be consummated. The Company’s stockholders and other investors are urged to read the Transaction Statement and the exhibits to the Transaction Statement carefully because they contain important information about the Private Placement, the Refinancing, any potential Take Private Transaction, and other transactions that may be deemed in furtherance of a “going-private” transaction. The Transaction Statement and the exhibits to the Transaction Statement can be found on the SEC’s website at www.sec.gov. In addition, copies of these documents can be obtained, without charge, by contacting Accelmed LP at Ugland House, South Church Street, PO Box 309, Grand Cayman KY1-1104, Cayman Islands. As of the date of this release, the Filing Persons have not entered into definitive agreements to effect a Take Private Transaction. If and when the Filing Persons determine to proceed with a Take Private Transaction and establish the terms thereof, the Transaction Statement will be amended at such time to disclose the terms of such Take Private Transaction, and the Company will file such amendment with the SEC and will prepare and cause to be mailed the amended Transaction Statement to its stockholders as required by law. In addition to receiving the amended Transaction Statement by mail, stockholders will be able to obtain the final Transaction Statement without charge, on the SEC’s website at www.sec.gov. In addition, copies of these documents can be obtained, without charge, by contacting Accelmed LP at Ugland House, South Church Street PO Box 309, Grand Cayman KY1-1104, Cayman Islands. SECURITYHOLDERS ARE URGED TO READ THESE MATERIALS AND OTHER MATERIAL FILED WITH OR FURNISHED TO THE SEC CAREFULLY WHEN THEY BECOME AVAILABLE, AS THEY WILL CONTAIN IMPORTANT INFORMATION. This announcement is neither a solicitation of proxy, an offer to purchase nor a solicitation of an offer to sell any securities and it is not a substitute for any proxy statement or other filings that may be made with the SEC should a Take Private Transaction occur. About Accelmed Accelmed is a U.S.-based private equity firm focused on acquiring and investing in U.S. commercial stage, lower middle market HealthTech companies. Since 2009, Accelmed has deployed over half a billion dollars into companies spanning medical devices, diagnostics, digital health and technology-enabled healthcare services. Accelmed seeks to accelerate value and scale innovation across the HealthTech field by bringing to bear the team’s industry experience, operational and financial expertise, and strong global relationships. For more information, please visit www.accelmed.com. Forward-Looking Statements This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Exchange Act. Forward-looking statements are based on management’s current assumptions and expectations of future events and trends, and actual results may differ materially from those expressed or implied in such statements due to numerous risks and uncertainties. Forward-looking statements may include, but are not limited to, statements regarding the closing of the Private Placement and the Accelmed LP’s ownership of the Common Stock upon the closing of the Private Placement. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Actual results may differ materially from these statements and from actual or future events due to a variety of factors. Because forward-looking statements are inherently subject to risks and uncertainties, you should not rely on these forward-looking statements as predictions of future events. All statements other than statements of historical fact are forward-looking statements. Except to the extent required by law, the Filing Persons undertake no obligation to update or review any estimate, projection, or forward-looking statement. Contact Details Accelmed Steve Rubin +1 914-364-0284 steve@accelmed.com Company Website https://www.accelmed.com

September 29, 2023 11:45 AM Eastern Daylight Time

Voyageur Pharmaceuticals "sees a gap in the market" for domestically-produced barium

Voyageur Pharmaceuticals Ltd

Proactive Research Analyst Daniel Appiah speaks to Thomas Warner from the Londons studio after publishing a new research note on Canadian medical imaging contrast media company Voyageur Pharmaceuticals Ltd (TSX-V:VM) (OTC:VYYRF). Appiah gives an overview of the note and the company itself, explaining that contrast agents containing barium sulphate or iodine are consumed prior to x-rays or CT scans, aiding doctors in visualizing the interior of the body. Voyageur aims to leverage its own facilities and resources to establish an integrated value chain for these agents in North America. The company has already launched its first product in Canada, with plans to expand to the US post-FDA approvals. By 2025, Voyageur intends to source barium from its fully-owned Frances Creek Mine, potentially reducing raw ingredient costs significantly. Appiah explains that Voyageur is currently seeking funding to help support its development. Contact Details Proactive Investors +1 604-688-8158 na-editorial@proactiveinvestors.com

September 28, 2023 02:02 PM Eastern Daylight Time

Video

News Release

1606 announces launch of ChatCBD, a revolutionary AI chatbot to enhance customer experiences

1606 Corp.

1606 Corp CEO Greg Lambrecht joined Proactive's Steve Darling with news the company is launching ChatCBD, an AI chatbot designed to revolutionize the customer experience. Lambrecht explained that ChatCBD, a conversational e-commerce tool, is set to debut through a partnership with Cool Blue Distribution. This strategic collaboration will enable 1606 to integrate its proprietary AI merchandizing ChatBot into Cool Blue's website. ChatCBD has been custom-tailored to provide comprehensive responses to customer inquiries related to CBD and offer product recommendations from the range of retail brands available through Cool Blue Distribution, a leading CBD distributor in the United States. The chatbot's standout feature lies in its utilization of Natural Language Processing (NLP) technology, which equips it with the capability to comprehend and respond to customer queries with a high degree of precision and understanding, akin to human interactions. Furthermore, ChatCBD operates 24/7, ensuring that customers receive assistance and solutions to their questions promptly, even beyond regular business hours. This innovative approach not only enhances the customer experience but also showcases 1606 Corp's commitment to leveraging cutting-edge technology to provide valuable solutions in the growing CBD market. By offering an AI-driven chatbot for CBD-related inquiries and product recommendations, 1606 Corp aims to create a seamless and informative shopping experience for consumers exploring the world of CBD products. Contact Details Proactive Canada +1 604-688-8158 na-editorial@proactiveinvestors.com

September 28, 2023 01:46 PM Eastern Daylight Time

Video

Joshua Borders Appointed as CEO of AmeriLife’s Senior Market Advisors

AmeriLife

Senior Market Advisors (SMA), a fast-growing field marketing organization (FMO) in the health insurance space and an affiliate of AmeriLife Group, LLC (“AmeriLife”), today announced the appointment of Joshua Borders to principal and chief executive officer. Borders, who succeeds SMA founder Jeff Pitta, was previously founder and managing partner of Buffalo Health Advisors, a Nashville-based insurance distributor and downline affiliate of SMA that specializes in Medicare Advantage, Medicare Supplement, PDP solutions, and health insurance for the under-65 market. At Buffalo, Borders oversaw a nationwide network of more than 500 field agents and grew the business 20% year-over-year for nine straight years, establishing the company as a top MAPD distributor in the state. Borders began his career as an independent sales agent focused on the Medicare Advantage market, bringing with him a client-centered approach and relentless focus on empowering agents with the tools and resources they need for success. “I’m grateful for the opportunity to lead SMA alongside an amazing team and our partners at AmeriLife,” said Borders. “SMA’s story is one of continued success, thanks in large part to an approach that isn’t content being just any FMO. SMA has – and will continue to be – a true difference-maker in the lives of the agents we help, the clients they serve, and the communities we support.” Founded in 2007, SMA boasts over 9,000 agents across 49 states, providing them with access to top Medicare and health insurance contracts, as well as life insurance and other products to help them serve the senior market. SMA is highly regarded for its best-in-class training, expert marketing support, and robust technology platforms that are designed by and for agents to better manage and grow their books of business, and support and scale growing independent marketing organizations (IMOs). SMA became an affiliate of AmeriLife in 2021. SMA is also deeply committed to putting people over profits. Since its founding, SMA has pledged more than $10 million to charities and community organizations locally and around the world, including to organizations such as Feeding America, King’s Kids Africa, and global nonprofit charity: water. “SMA has written the playbook on what it takes to be a successful FMO,” said Robert “Bobby” Bache, vice president of Life and Health Distribution for AmeriLife Health. “I’m grateful for Josh’s partnership and confident that, under his direction, SMA will continue to raise the bar in our industry.” “I want to thank Jeff for his many years of service at SMA and congratulate Josh on his new role,” added Scotty Elliot, Chief Distribution Officer for AmeriLife Health. “Josh’s appointment is a testament to his leadership, business acumen, and agent-first mindset. I believe he’s the perfect choice to lead SMA, and I couldn’t be more excited for the road ahead.” ### About Senior Market Advisors Senior Market Advisors (SMA) has been putting people over profits since 2007, through hard work and a commitment to “doing right” by the consumer. We know the grit and determination involved in becoming a career agent. And as a result, we have become one of the fastest growing FMOs, doubling our business each year for the past five years. For more information, visit us online at SeniorMarketAdvisors.com. About AmeriLife AmeriLife’s strength is its mission: to provide insurance and retirement solutions to help people live longer, healthier lives. In doing so, AmeriLife has become recognized as the leader in developing, marketing, and distributing life and health insurance, annuities, and retirement planning solutions to enhance the lives of pre-retirees and retirees across the United States. For more than 50 years, AmeriLife has partnered with top insurance carriers to provide value and quality to customers served through a distribution network of over 300,000 insurance agents and advisors and more than 100 marketing organizations and insurance agency locations nationwide. For more information, visit AmeriLife.com, and follow AmeriLife on Facebook and LinkedIn. Contact Details Media Jeff Maldonado +1 321-297-1112 jmaldonado@amerilife.com Partnership Inquiries Patrick Nichols +1 727-726-0726 pnichols@amerilife.com Company Website https://amerilife.com/

September 28, 2023 01:00 PM Eastern Daylight Time

1 ... 52 53 54 55 56 ... 269